Safety and efficacy of everolimus (EVE) as second-line treatment in neuroendocrine neoplasms G3 (NEN G3): An AIO phase II study (EVINEC)

被引：1
|
作者：
Pavel, M. E. [1 ]
von Weikersthal, L. Fischer [2 ]
Kloeppel, G. [3 ]
Krause, K. [4 ]
Apostolidis, L. [5 ]
机构：
[1] Univ Klin Erlangen, Endocrinol Dept, Gastroenterol & Hepatol, Erlangen, Germany
[2] Klinikum St Marien Amberg, Onkolog Zentrum, Amberg, Germany
[3] Tech Univ Munich, Inst Pathol, Munich, Germany
[4] AIO Studien gGmbH, Project Management Dept, Berlin, Germany
[5] Natl Ctr Tumor Dis NCT, Dept Med Oncol, Heidelberg, Germany
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.717
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1184MO
引用
收藏
页码：S702 / S702
页数：1
相关论文
共 50 条
  • [1] Safety and efficacy of everolimus (EVE) as second-line treatment in neuroendocrine neoplasms G3 (NEN G3) - an AIO phase II study (EVINEC)
    Pavel, Marianne
    Kloeppel, Guenter
    von Weikersthal, Ludwig Fischer
    Hoersch, Dieter
    Mayer, Karin
    Schrader, Joerg
    Augustin, Marinela
    Venerito, Marino
    Krause, Katrin
    Apostolidis, Leonidas
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 236 - 236
  • [2] Treatment outcomes of patients with G3 neuroendocrine neoplasms
    Jann, Henning
    Kayser, Antonin
    Wiedenmann, Bertram
    Tacke, Frank
    Roderburg, Christoph
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [3] Treatment outcomes of patients with G3 neuroendocrine neoplasms
    Jann, H.
    Wiedenmann, B.
    Tacke, F.
    Roderburg, C.
    JOURNAL OF NEUROENDOCRINOLOGY, 2021, 33 : 137 - 137
  • [4] Treatment Outcomes of Patients with G3 Neuroendocrine Neoplasms
    Schenk, J.
    Kayser, A.
    Wiedenmann, B.
    Tacke, F.
    Roderburg, C.
    Jann, H.
    NEUROENDOCRINOLOGY, 2020, 110 : 203 - 203
  • [5] Everolimus in Pancreatic Neuroendocrine Carcinomas G3
    Panzuto, F.
    Rinzivillo, M.
    Spada, F.
    Antonuzzo, L.
    Ibrahim, T.
    Campana, D.
    Fazio, N.
    Delle Fave, G.
    NEUROENDOCRINOLOGY, 2016, 103 : 83 - 83
  • [6] Everolimus in Pancreatic Neuroendocrine Carcinomas G3
    Panzuto, Francesco
    Rinzivillo, Maria
    Spada, Francesca
    Antonuzzo, Lorenzo
    Ibrahim, Toni
    Campana, Davide
    Fazio, Nicola
    Delle Fave, Gianfranco
    PANCREAS, 2017, 46 (03) : 302 - 305
  • [7] Are G3 ENETS neuroendocrine neoplasms heterogeneous?
    Velayoudom-Cephise, Fritz-Line
    Duvillard, Pierre
    Foucan, Lydia
    Hadoux, Julien
    Chougnet, Cecile N.
    Leboulleux, Sophie
    Malka, David
    Guigay, Joel
    Goere, Diane
    Debaere, Thierry
    Caramella, Caroline
    Schlumberger, Martin
    Planchard, David
    Elias, Dominique
    Ducreux, Michel
    Scoazec, Jean-Yves
    Baudin, Eric
    ENDOCRINE-RELATED CANCER, 2013, 20 (05) : 649 - 657
  • [8] Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms
    Heetfeld, M.
    Chougnet, C. N.
    Olsen, I. H.
    Rinke, A.
    Borbath, I.
    Crespo, G.
    Barriuso, J.
    Pavel, M.
    O'Toole, D.
    Walter, T.
    ENDOCRINE-RELATED CANCER, 2015, 22 (04) : 657 - 664
  • [9] Phase II study of everolimus and temozolomide as 1-line treatment in metastatic high-grade gastroenteropancreatic neuroendocrine neoplasms (NET G3 and NEC)
    Morken, S.
    Langer, S. W.
    Sundlov, A.
    Detlefsen, S.
    Krogh, M.
    Tabaksblat, E.
    Hjortland, G. O.
    Svensson, J. B.
    Assmus, J.
    Couvelard, A.
    Perren, A.
    Sorbye, H.
    JOURNAL OF NEUROENDOCRINOLOGY, 2022, 34 : 181 - 181
  • [10] Genetic profile of pancreatic neuroendocrine neoplasms G3
    Konukiewitz, B.
    Jesinghaus, M.
    Schlitter, A. M.
    Kasajima, A.
    Steiger, K.
    Zamboni, G.
    Weichert, W.
    Kloeppel, G.
    Pfarr, N.
    VIRCHOWS ARCHIV, 2017, 471 : S7 - S7
12345